IP Library Granted Patent US 10,085,939
Granted Patent B2
US 10,085,939 · App. 14/824,787 · Granted Oct 2, 2018

Composition of dexibuprofen transdermal hydrogel

Inventors: Jeffrey Stuart Bergman (Hertfordshire, GB); Sampathkumar Devarajan (Chennai, IN); Selvakumar Ramalingam (Tamil Nadu, IN); Anandsenthil Vel Palanisamy (Tamil Nadu, IN)
Assignee: Strides Shasun Limited
A61K9/06A61K9/0014A61K31/192A61K47/02A61K47/12A61K47/18A61K47/10A61K47/32A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,085,939
App. No.
14/824,787
Granted
Oct 2, 2018
Kind
B2
Abstract

Stable non-alcoholic transdermal hydrogel of dexibuprofen was prepared by using a simple manufacturing process, and the experimental trials showed that the pH modifying agent, antioxidant and water miscible solvent are the essential excipients to obtain stable non-alcoholic transdermal hydrogel of dexibuprofen. The dexibuprofen hydrogel prepared using carbopol as a gelling polymer produced an opaque gel, whereas hydrogel prepared using hyroxypropyl methylcellulose (HPMC) as a gelling polymer produced a transparent gel. There was no significant changes observed with respect to physical description, pH, assay and particularly to the related substance values when the hydrogels were subjected to the stability study at accelerated condition (40° C./75% RH) for 3 months in laminated tubes.

Claims (13)

1. A transdermal hydrogel composition consisting essentially of, by weight % of the composition,

1% to 15% dexibuprofen;

0.5% to 30% of a combination of three gelling agents wherein the first gelling agent is selected from one of HPMC K4M and hydroxy ethyl cellulose, the second gelling agent is HPMC E5, and the third gelling agent is poloxamer 188;

0.1% to 20% of a permeation enhancer consisting of diethylene glycol monoethyl ether;

sodium hydroxide;

0.05% to 5% of an antioxidant consisting of sodium metabisulfite;

two water miscible solvents consisting of polyethylene glycol and propylene glycol;

one or more preservative;

one or more soothing agent; and

water to total 100%.

2. The transdermal hydrogel composition according to claim 1 , wherein the one or more preservative consists of sodium benzoate, and the one or more soothing agent consists of menthol.

3. The transdermal hydrogel composition according to claim 1 , wherein the weight % of dexibuprofen is 10%.

4. The transdermal hydrogel composition according to claim 1 , wherein the weight % of dexibuprofen is 5%.

Assignments (4)
CHANGE OF NAME Recorded Aug 24, 2018
From: STRIDES SHASUN LIMITED
To: STRIDES PHARMA SCIENCE LIMITED
Reel/Frame 046942/0762 →
CHANGE OF NAME Recorded Jan 23, 2017
From: STRIDES ARCOLAB LIMITED
To: STRIDES SHASUN LIMITED
Reel/Frame 041041/0351 →
MERGER Recorded Jan 23, 2017
From: SHASUN PHARMACEUTICALS LIMITED
To: STRIDES ARCOLAB LIMITED
Reel/Frame 041061/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2015
From: BERGMAN, JEFFREY STUART; DEVARAJAN, SAMPATHKUMAR; RAMALINGAM, SELVAKUMAR; PALANISAMY, ANANDSENTHIL VEL
To: SHASUN PHARMACEUTICALS LIMITED
Reel/Frame 036311/0780 →
Continuity (2)
Continuation 13525432 · Jun 18, 2012
Related Publication 20150342879A1 · Dec 3, 2015